iShares Genomics Immunology and Healthcare ETF (IDNA) Stock Forecast
Alert
Its only available to paid users.
N/A
Based on the iShares Genomics Immunology and Healthcare ETF stock forecast from 0 analysts, the average analyst target price for iShares Genomics Immunology and Healthcare ETF is not available over the next 12 months. iShares Genomics Immunology and Healthcare ETF’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of iShares Genomics Immunology and Healthcare ETF is Very Bearish, which is based on 0 positive signals and 5 negative signals. At the last closing, iShares Genomics Immunology and Healthcare ETF’s stock price was USD 21.94. iShares Genomics Immunology and Healthcare ETF’s stock price has changed by +0.46% over the past week, -7.93% over the past month and -6.72% over the last year.
No recent analyst target price found for iShares Genomics Immunology and Healthcare ETF
No recent average analyst rating found for iShares Genomics Immunology and Healthcare ETF
Company Overview iShares Genomics Immunology and Healthcare ETF
The fund generally will invest at least 80% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. -null-. Read Less
The fund generally will invest at least 80% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 20% of its assets in certain fut...Read More
N/A
N/A
N/A
N/A
USD
USA
11/06/2019
NYSE Fctet Glb Gnmcs&Imm Biophrm USD
N/A
0.47 %
Adjusted Closing Price for iShares Genomics Immunology and Healthcare ETF (IDNA)
Loading...
Unadjusted Closing Price for iShares Genomics Immunology and Healthcare ETF (IDNA)
Loading...
Share Trading Volume for iShares Genomics Immunology and Healthcare ETF Shares
Loading...
Compare Performance of iShares Genomics Immunology and Healthcare ETF Shares
Frequently Asked Questions About iShares Genomics Immunology and Healthcare ETF (IDNA) Stock
Stock Target Advisor's fundamental analysis for iShares Genomics Immunology and Healthcare ETF's stock is Very Bearish.
IDNA stock's dividend yield is 0.99%.
Our analysis grades IDNA stock's dividend yield at D-. This means that IDNA stock's dividend yield is above 61% of the stocks in the Health sector in the NYE exchange.
Based on this IDNA may be a average dividend stock for its sector.
Unfortunately we do not have enough data on IDNA's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on IDNA's stock to indicate if its overvalued.
The last closing price of IDNA's stock was USD 21.94.
The most recent market capitalization for IDNA is USD 0.14B.
Unfortunately we do not have enough analyst data on IDNA's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains iShares Genomics Immunology and Healthcare ETF's stock.
Sorry, we do not have any data on the number of employees for iShares Genomics Immunology and Healthcare ETF.
Sorry we do not have any infomation available on iShares Genomics Immunology and Healthcare ETF's address.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for IDNA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
